Literature DB >> 33238139

Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life.

Laura P Cohen1, Eric Vittinghoff2, Mark J Pletcher2, Norrina B Allen3, Sanjiv J Shah3, John T Wilkins3, Patricia P Chang4, Chiadi E Ndumele5, Anne B Newman6, Diane Ives6, Mathew S Maurer1, Elizabeth C Oelsner1, Andrew E Moran1, Yiyi Zhang7.   

Abstract

BACKGROUND: Independent associations between cardiovascular risk factor exposures during midlife and later life development of heart failure (HF) with preserved ejection fraction (HFpEF) versus reduced EF (HFrEF) have not been previously studied.
METHODS: We pooled data from 4 US cohort studies (Atherosclerosis Risk in Communities, Cardiovascular Health, Health , Aging and Body Composition, and Multi-Ethnic Study of Atherosclerosis) and imputed annual risk factor trajectories for body mass index, systolic and diastolic blood pressure, low-density lipoprotein and high-density lipoprotein cholesterol, and glucose starting from age 40 years. Time-weighted average exposures to each risk factor during midlife and later life were calculated and analyzed for associations with the development of HFpEF or HFrEF.
RESULTS: A total of 23,861 participants were included (mean age at first in-person visit, 61.8 ±1 0.2 years; 56.6% female). During a median follow-up of 12 years, there were 3666 incident HF events, of which 51% had EF measured, including 934 with HFpEF and 739 with HFrEF. A high midlife systolic blood pressure and low midlife high-density lipoprotein cholesterol were associated with HFrEF, and a high midlife body mass index, systolic blood pressure, pulse pressure, and glucose were associated with HFpEF. After adjusting for later life exposures, only midlife pulse pressure remained independently associated with HFpEF.
CONCLUSIONS: Midlife exposure to cardiovascular risk factors are differentially associated with HFrEF and HFpEF later in life. Having a higher pulse pressure during midlife is associated with a greater risk for HFpEF but not HFrEF, independent of later life exposures.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure subtype; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; midlife; risk factors

Mesh:

Year:  2020        PMID: 33238139      PMCID: PMC7987686          DOI: 10.1016/j.cardfail.2020.11.008

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  46 in total

Review 1.  Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management.

Authors:  Patrick Meagher; Mohamed Adam; Robert Civitarese; Antoinette Bugyei-Twum; Kim A Connelly
Journal:  Can J Cardiol       Date:  2018-03-02       Impact factor: 5.223

Review 2.  The Transition From Hypertension to Heart Failure: Contemporary Update.

Authors:  Franz H Messerli; Stefano F Rimoldi; Sripal Bangalore
Journal:  JACC Heart Fail       Date:  2017-07-12       Impact factor: 12.035

Review 3.  The pathophysiology of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

4.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

5.  Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.

Authors:  S S Franklin; M G Larson; S A Khan; N D Wong; E P Leip; W B Kannel; D Levy
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

Review 6.  Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.

Authors:  Kelly McHugh; Adam D DeVore; Jingjing Wu; Roland A Matsouaka; Gregg C Fonarow; Paul A Heidenreich; Clyde W Yancy; Jennifer B Green; Natasha Altman; Adrian F Hernandez
Journal:  J Am Coll Cardiol       Date:  2019-02-12       Impact factor: 24.094

7.  Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

Authors:  Franz H Messerli; Giuseppe Mancia; C Richard Conti; Ann C Hewkin; Stuart Kupfer; Annette Champion; Rainer Kolloch; Athanase Benetos; Carl J Pepine
Journal:  Ann Intern Med       Date:  2006-06-20       Impact factor: 25.391

Review 8.  Epidemiology and risk profile of heart failure.

Authors:  Anh L Bui; Tamara B Horwich; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2010-11-09       Impact factor: 32.419

9.  Survival associated with two sets of diagnostic criteria for congestive heart failure.

Authors:  Gina D Schellenbaum; Thomas D Rea; Susan R Heckbert; Nicholas L Smith; Thomas Lumley; Veronique L Roger; Dalane W Kitzman; Herman A Taylor; Daniel Levy; Bruce M Psaty
Journal:  Am J Epidemiol       Date:  2004-10-01       Impact factor: 4.897

10.  Risk factors for heart failure: a population-based case-control study.

Authors:  Shannon M Dunlay; Susan A Weston; Steven J Jacobsen; Véronique L Roger
Journal:  Am J Med       Date:  2009-11       Impact factor: 4.965

View more
  2 in total

1.  Cost-Effectiveness of Masked Hypertension Screening and Treatment in US Adults With Suspected Masked Hypertension: A Simulation Study.

Authors:  Matthew B Green; Daichi Shimbo; Joseph E Schwartz; Adam P Bress; Jordan B King; Paul Muntner; James P Sheppard; Richard J McManus; Ciaran N Kohli-Lynch; Yiyi Zhang; Steven Shea; Andrew E Moran; Brandon K Bellows
Journal:  Am J Hypertens       Date:  2022-08-01       Impact factor: 3.080

2.  Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.

Authors:  Federico Guerra; Ernesto Ammendola; Matteo Ziacchi; Vittorio Aspromonte; Pier Luigi Pellegrino; Giuseppe Del Giorno; Gabriele Dell'Era; Lorenzo Pimpini; Francesco Santoro; Roberto Floris; Giulia Stronati; Gerardo Nigro; Pasquale Paolisso; Alessandro Guido; Giampiero Maglia; Natale Daniele Brunetti; Angelo Carbone; Miriam Gravellone; Roberto Antonicelli; Michele Cannone; Michele Accogli; Antonio Dello Russo; Pietro Palmisano
Journal:  Eur J Clin Pharmacol       Date:  2021-07-19       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.